VMD Sciences, a pioneering company in biomedical innovation for pets, has launched Expanded Access Programs (EAPs) for pets and livestock. These programs provide access to innovative life-saving treatments that are often not accessible through traditional channels.
EAPs, commonly used in human medicine, grant access to unlicensed therapies for unmet medical needs. VMD Sciences is now introducing these programs to the veterinary sector, offering hope for pets with limited treatment options.
VMD Sciences understands the urgent need for ethical and compliant access to global veterinary medicines. They collaborate with veterinarians and pharmaceutical manufacturers to facilitate access to treatments that adhere to regulatory guidelines.
The company’s robust global network for approved drug distribution allows veterinarians to initiate product inquiries directly through their website. This ensures a seamless process for obtaining these vital medications.
VMD Sciences believes that EAPs will enhance the health of pets and livestock while advancing medical knowledge through translational medicine. By providing access to cutting-edge treatments, the company aims to support veterinarians, pet owners, and the overall well-being of animals.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
